Kiplinger

The 7 Best Biotech Stocks for Investors Who Hate Risk

Most of the buy-and-hold crowd tends to steer clear of biotech stocks, and for good reason. Biotechnology companies can be uncomfortably risky. Far too many horror stories of failed drug trials or the expiration of a crucial patent leading to massive stock plunges have circulated for years now, souring would-be buyers on the entire industry.

However, conclusions based on a handful of biotech stocks may have erroneously prevented investors from plugging into a perfectly reasonable risk-reward relationship. Said differently: Not all biotech stocks turn into disasters. The industry as a group is up nearly 70% for the past five years, proving many of these companies can reward patient shareholders who choose wisely. It's simply a matter of doing your homework and having a little common sense.

Here are seven biotech stocks that aren't nearly as risky as their typical peer. Thus, they may have a place in more risk-averse portfolios than most investors might presume.

Amgen

Market value: $132.3 billion

The biggest biopharmaceutical companies don't always win all the spoils. A small outfit with a novel idea and a little know-how certainly is capable of coming

You're reading a preview, sign up to read more.

More from Kiplinger

Kiplinger3 min read
Prepare For Detours In The Market: Manage Your Plan In Real-Time
Once you've created an income plan for your retirement, don't think you're done when the numbers on paper meet your immediate expectations. A successful plan requires regular analysis and adjustments. Both might be required, either because your goals
Kiplinger3 min read
Don't Let Bad Timing Be Your Biggest Retirement Mistake
Despite cautionary tales you might hear about how Americans are failing at saving for retirement, plenty of people get it right. They work hard and start saving early. They make the most of 401(k) and other investment accounts, and they accumulate a
Kiplinger2 min read
How the Stock Market Performed During the Clinton Impeachment
Investors might be concerned that the impeachment trial of President Donald Trump, which began Thursday, Jan. 17, could cast a pall over the stock market's recent run to all-time highs. But if past is prologue, the market will shrug this off. In fact